You are viewing: Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market analysis

The Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market was valued at $12.58 Million in 2025 and projected to reach to $15.52 Million by 2030, representing a compound annual growth rate of 4.3%. Saudi Arabia's IVD Quality Control Market is positioned for steady growth through 2030, supported by the kingdom's commitment to healthcare modernization under Vision 2030.

Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market Trends and Insights

  • This steady growth reflects Saudi Arabia's increasing investment in healthcare infrastructure and diagnostic capabilities as part of its Vision 2030 modernization agenda.
  • The market in Saudi Arabia is driven by rising demand for accurate laboratory testing, stringent regulatory requirements, and the expansion of diagnostic facilities across the kingdom. Saudi Arabia's healthcare sector continues to prioritize quality assurance in diagnostic testing, supporting the adoption of advanced quality control solutions.
  • The market in Saudi Arabia benefits from government initiatives promoting domestic healthcare capacity and the establishment of new diagnostic centers.
  • As Saudi Arabia strengthens its position as a regional healthcare hub, the IVD quality control market is expected to experience sustained demand through 2030, supported by both public and private sector investments in laboratory modernization and compliance infrastructure..

Key Market Statistics

  • CAGR (2025-2030) 4.3% CAGR
  • Market Size, 2025 ~USD 12.58 Million
  • Forecast, 2030 ~USD 15.52 Million
  • Country Saudi Arabia

Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market Overview

Vision 2030 Healthcare Investment :

Saudi Arabia's Vision 2030 initiative is driving substantial investments in healthcare infrastructure and diagnostic capabilities, directly supporting IVD quality control market expansion and modernization of laboratory facilities across the kingdom.

Steady Market Growth Trajectory :

The Saudi Arabia IVD Quality Control Market is experiencing consistent growth at 4.3% CAGR, with market valuation increasing from USD 12.58 million in 2025 to USD 15.52 million by 2030, reflecting sustained demand for quality assurance in diagnostics.

Regulatory Compliance Emphasis :

Increasing regulatory requirements from Saudi health authorities and alignment with international quality standards are driving adoption of advanced IVD quality control solutions across hospitals, diagnostic centers, and clinical laboratories throughout the region.

Growing Diagnostic Testing Demand :

Rising prevalence of chronic diseases, expanding population health screening programs, and increased healthcare accessibility in Saudi Arabia are generating higher volumes of diagnostic tests, necessitating robust quality control mechanisms.

Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market Dynamics

  • Government initiatives promoting domestic healthcare capabilities and reducing dependency on imported diagnostic services are creating favorable conditions for market expansion.
  • The market benefits from increasing laboratory automation, rising awareness of diagnostic accuracy, and strengthened regulatory frameworks. Key growth drivers include expanding private healthcare sector investments, establishment of new diagnostic centers, and enhanced training programs for laboratory professionals.
  • As Saudi Arabia continues developing its healthcare ecosystem and improving diagnostic infrastructure, demand for quality control solutions will intensify.
  • The market's 4.3% CAGR reflects sustainable growth potential, with opportunities emerging from technological adoption and compliance with international quality standards across the healthcare system..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Saudi Arabia's IVD Quality Control Market is valued at USD 12.58 million in 2025 with a projected value of USD 15.52 million by 2030.
      • The market in Saudi Arabia is growing at a CAGR of 4.3%, driven by healthcare modernization and regulatory compliance requirements.
      • Saudi Arabia's Vision 2030 initiative supports expansion of diagnostic infrastructure and quality control adoption across the kingdom.
      • Government investment in healthcare capacity and private sector growth are key drivers of the IVD quality control market in Saudi Arabia.

      In Vitro Diagnostics (IVD) Quality Control Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MOLECULAR DIAGNOSTICS (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 5.5% from 2025 to 2030
      Largest Segment QUALITY CONTROL PRODUCTS (Product & Service)
      Market Size Base Year (Billions) ~USD 1.65 (2025)
      Revenue Forecast (Billions) ~USD 2.15 (2030)
      Segments Covered Product & Service, Type, Technology, Manufacturer Type, End User

      Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product & Service

      • Data Management Solutions
      • Quality Assurance Services
      • Quality Control Products

      By Type

      • Independent Controls
      • Instrument-Specific Controls
      • Other Controls
      • Serum/Plasma-Based Controls
      • Urine-Based Controls
      • Whole Blood-Based Controls

      By Technology

      • Clinical Chemistry
      • Coagulation & Hemostasis
      • Hematology
      • Immunoassays
      • Microbiology
      • Molecular Diagnostics
      • Other Technologies

      By Manufacturer Type

      • Original Equipment Manufacturer Controls
      • Third-Party Controls

      By End User

      • Academic & Research Institutes
      • Clinical Laboratories
      • Hospitals
      • Other End Users

      Target Audience

      • Diagnostic Equipment Manufacturers : Manufacturers need Saudi Arabia-specific market data to develop localized product strategies, understand quality control requirements, and identify distribution partnerships aligned with Vision 2030 healthcare initiatives.
      • Healthcare Facility Operators : Hospital administrators and diagnostic center operators require market insights to benchmark quality control investments, plan laboratory upgrades, and ensure compliance with evolving Saudi regulatory standards.
      • Quality Control Solution Providers : IVD quality assurance vendors need detailed Saudi market analysis to assess demand for their solutions, identify customer segments, and develop competitive positioning strategies for the growing kingdom market.
      • Healthcare Investment Firms : Private equity and healthcare investors need comprehensive Saudi Arabia market data to evaluate investment opportunities in diagnostic infrastructure, assess growth potential, and make informed funding decisions.
      • Laboratory Management Consultants : Consulting firms advising healthcare organizations require Saudi-specific market intelligence to guide clients on quality control best practices, technology adoption, and regulatory compliance strategies.

      Key Companies in the Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market

      CompanyHQOwnershipStrongest segments
      BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers),
      CEPHEID INC.United StatesPrivate CompanyGeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS),
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products,
      DIASORINItalyPublic CompanyImmunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers,
      UNILABSSwitzerlandPrivate CompanyCore laboratory testing,Medical imaging services,Pathology and centres of excellence,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services,
      THERMO FISHER SCIENTIFIC, INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula),
      LGC LIMITEDSouth KoreaPublic CompanyEthylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
      QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC),
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers,
      BIO-TECHNE CORPORATIONUnited StatesPublic CompanyProtein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays,
      MICROBIX BIOSYSTEMS INC.CanadaPublic CompanyAntigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium,
      GRIFOLS, S.A.SpainPublic CompanyBiopharma (plasma-derived medicines),Diagnostic,Bio Supplies,

      BIOMERIEUX S.A.

      bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

      CEPHEID INC.

      Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.

      IMMUCOR, INC.

      Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.

      DIASORIN

      DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.

      UNILABS

      Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.

      THERMO FISHER SCIENTIFIC, INC.

      Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

      ABBOTT

      Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.

      LGC LIMITED

      LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.

      QUIDELORTHO CORPORATION

      QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.

      DANAHER CORPORATION

      Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.

      SYSMEX CORPORATION

      Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.

      BIO-TECHNE CORPORATION

      Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.

      MICROBIX BIOSYSTEMS INC.

      Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.

      GRIFOLS, S.A.

      Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.

      Reasons to Buy this Report

      • Market-Specific Growth Projections : Access precise valuation data for Saudi Arabia's IVD Quality Control Market with detailed forecasts through 2030, enabling accurate business planning and investment decisions tailored to the kingdom's unique market dynamics.
      • Vision 2030 Alignment Insights : Understand how Saudi Arabia's Vision 2030 healthcare modernization agenda directly impacts IVD quality control demand, regulatory requirements, and investment opportunities within the diagnostic sector.
      • Competitive Market Intelligence : Gain comprehensive analysis of Saudi Arabia's diagnostic landscape, including market drivers, regulatory environment, and competitive positioning to inform market entry strategies and expansion plans.
      • Sector-Specific Opportunity Identification : Identify high-growth segments within Saudi Arabia's IVD quality control market, including emerging technologies, underserved regions, and partnership opportunities with local healthcare providers and laboratories.
      • Risk Assessment & Regulatory Guidance : Evaluate market risks, regulatory compliance requirements, and healthcare infrastructure developments specific to Saudi Arabia to mitigate business risks and ensure successful market penetration.

      Frequently asked questions

      What is the current market size of IVD Quality Control in Saudi Arabia?

      Saudi Arabia's IVD Quality Control Market is valued at USD 12.58 million in 2025.

      What is the projected market size for Saudi Arabia by 2030?

      The market in Saudi Arabia is projected to reach USD 15.52 million by 2030.

      What is the CAGR for the IVD Quality Control Market in Saudi Arabia?

      Saudi Arabia's IVD Quality Control Market is growing at a CAGR of 4.3% from 2025 to 2030.

      What factors are driving growth in Saudi Arabia's IVD Quality Control Market?

      Growth in Saudi Arabia is driven by healthcare infrastructure modernization, regulatory compliance requirements, Vision 2030 initiatives, and expansion of diagnostic facilities.

      How does Saudi Arabia's market compare to global trends?

      Saudi Arabia's CAGR of 4.3% is slightly below the global CAGR of 5.5%, reflecting a more measured but steady growth trajectory in the kingdom's diagnostic quality control sector.

      RESEARCH METHODOLOGY

      The study involved major activities in estimating the current market size for the global IVD quality controls market.

      Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.

      The four steps involved in estimating the market size are as follows:

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      The following is a breakdown of the primary respondents:

      In Vitro Diagnostics (IVD) Quality Control Market

      Note 1: Others include sales, marketing, and product managers.

      Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:

      In Vitro Diagnostics (IVD) Quality Control Market

      Data Triangulation

      After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.

      Stakeholders

      • Senior Management
      • End Users
      • Finance/Procurement Department
      • R&D Department

      Report Objectives

      • To define, describe, segment, and forecast the global IVD quality controls market by product & service, technology, manufacturer type, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall IVD quality controls market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
      • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
      • To benchmark players within the IVD quality controls market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

      Get the Full In Vitro Diagnostics (IVD) Quality Control Market Report

      Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status